Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Evaluation of anti-PD-1-based therapy against triple-negative breast cancer patient-derived xenograft tumors engrafted in humanized mouse models.

Rosato RR, Dávila-González D, Choi DS, Qian W, Chen W, Kozielski AJ, Wong H, Dave B, Chang JC.

Breast Cancer Res. 2018 Sep 5;20(1):108. doi: 10.1186/s13058-018-1037-4.

2.

Pharmacological Inhibition of NOS Activates ASK1/JNK Pathway Augmenting Docetaxel-Mediated Apoptosis in Triple-Negative Breast Cancer.

Dávila-González D, Choi DS, Rosato RR, Granados-Principal SM, Kuhn JG, Li WF, Qian W, Chen W, Kozielski AJ, Wong H, Dave B, Chang JC.

Clin Cancer Res. 2018 Mar 1;24(5):1152-1162. doi: 10.1158/1078-0432.CCR-17-1437. Epub 2018 Jan 4.

3.

NO and COX2: Dual targeting for aggressive cancers.

Davila-Gonzalez D, Chang JC, Billiar TR.

Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):13591-13593. doi: 10.1073/pnas.1717440114. Epub 2017 Dec 13. No abstract available.

4.

Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.

Balko JM, Schwarz LJ, Luo N, Estrada MV, Giltnane JM, Dávila-González D, Wang K, Sánchez V, Dean PT, Combs SE, Hicks D, Pinto JA, Landis MD, Doimi FD, Yelensky R, Miller VA, Stephens PJ, Rimm DL, Gómez H, Chang JC, Sanders ME, Cook RS, Arteaga CL.

Sci Transl Med. 2016 Apr 13;8(334):334ra53. doi: 10.1126/scitranslmed.aad3001. Erratum in: Sci Transl Med. 2019 Jan 23;11(476):.

Supplemental Content

Loading ...
Support Center